Home
About Galectin
Our Team
Our Pipeline
News
Investor Relations
Overview
Press Releases
Events & Presentations
Corporate Governance
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Annual Reports
Quarterly Results
Stock Information
Historic Stock Lookup
Analyst Coverage
FAQs
Contact Us
News
Poster Presented at AASLD Annual Meeting by Exalenz Bioscience Based on Data Collected in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02
November 10, 2018 | Presentation
Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting
November 5, 2018 | Press Release
Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference
October 15, 2018 | Press Release
Read more
Corporate Update
An updated overview of the company's activities and Clinical Phase studies with the Galectin-3 inhibitor GR-MD-02.
EASL Presentation
A detailed review of the company's late-breaker presentation at The International Liver Congress, which reinforces and extends the positive effects of GR-MD-02 in patients with NASH cirrhosis.
NASH Summit
A detailed review of the company's keynote presentation at The 2nd Annual Nash Summit, providing in-depth insight on clinical trials and endpoints in NASH cirrhosis and an overview of the NASH-CX Clinical Trial.
Supplemental presentation on GR-MD-02 for Combination Cancer Immunotherapy
A detailed review of the use of GR-MD-02 in combination therapy with KEYTRUDA in advanced melanoma.
Galectin Therapeutics, Inc.
NASDAQ: GALT
Filings & Reports
Corporate Snapshot
Latest Corporate Presentation
Media Fact Sheet
Subscribe
Compassionate Use Policy
|
Privacy Policy
|
Terms of Use
|
Site Map
 Disclaimer: This site may contain 
forward-looking information

jQuery(document).on('ready post-load', easy_fancybox_handler );
